Tags

Type your tag names separated by a space and hit enter

Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status.

Abstract

Epidemiological and experimental studies suggest that isoflavones may protect against breast cancer by acting as estrogen agonists or antagonists. A case-control study was conducted in southeast China in 2004-2005 to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor (ER) and progesterone receptor (PR) status. The incident cases were 756 female patients with histologically confirmed breast cancer. The 1,009 age-matched controls were healthy women randomly recruited from outpatient breast clinics. We assessed isoflavone intake by face-to-face interview using a validated and reliable food-frequency questionnaire and obtained tumor ER and PR status from pathologic reports. Compared with women in the lowest intake quartiles, those in the highest quartile of total isoflavone intake had a reduced risk of all receptor status subtypes of breast cancer with a dose-response relationship. The adjusted ORs (95% CIs) were 0.39 (0.27-0.58) for ER+, 0.32 (0.21-0.49) for ER-, 0.43 (0.29-0.64) for PR+, and 0.30 (0.19-0.45) for PR- (P for trend <0.001). These inverse associations existed in both pre- and post-menopausal women after stratification. Stronger evidence of a protective effect of high isoflavone intake was observed for breast cancer tumors with concordant rather than discordant receptor status; i.e., those with ER+/PR+ (OR 0.39, 0.26-0.59) and ER-/PR- (OR 0.28, 0.17-0.44). The finding that isoflavones protect against all tumor subtypes of breast cancer have biological plausibility, being supported by evidence from experimental studies. Future studies are required to fully understand the complex regulation of isoflavone on breast cancer by tumor hormone status.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    School of Population Health, The University of Western Australia, 35 Stirling Highway, Crawley, Perth, WA, 6009, Australia. min.zhang@uwa.edu.au

    ,

    Source

    Breast cancer research and treatment 118:3 2009 Dec pg 553-63

    MeSH

    Adult
    Aged
    Aged, 80 and over
    Breast Neoplasms
    Case-Control Studies
    China
    Diet
    Diet Surveys
    Female
    Humans
    Isoflavones
    Middle Aged
    Odds Ratio
    Receptors, Estrogen
    Receptors, Progesterone
    Risk Factors
    Surveys and Questionnaires
    Young Adult

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    19252980

    Citation

    Zhang, Min, et al. "Dietary Intake of Isoflavones and Breast Cancer Risk By Estrogen and Progesterone Receptor Status." Breast Cancer Research and Treatment, vol. 118, no. 3, 2009, pp. 553-63.
    Zhang M, Yang H, Holman CD. Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status. Breast Cancer Res Treat. 2009;118(3):553-63.
    Zhang, M., Yang, H., & Holman, C. D. (2009). Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status. Breast Cancer Research and Treatment, 118(3), pp. 553-63. doi:10.1007/s10549-009-0354-9.
    Zhang M, Yang H, Holman CD. Dietary Intake of Isoflavones and Breast Cancer Risk By Estrogen and Progesterone Receptor Status. Breast Cancer Res Treat. 2009;118(3):553-63. PubMed PMID: 19252980.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status. AU - Zhang,Min, AU - Yang,Hongjian, AU - Holman,C D'Arcy J, Y1 - 2009/02/28/ PY - 2009/02/19/received PY - 2009/02/20/accepted PY - 2009/3/3/entrez PY - 2009/3/3/pubmed PY - 2010/1/23/medline SP - 553 EP - 63 JF - Breast cancer research and treatment JO - Breast Cancer Res. Treat. VL - 118 IS - 3 N2 - Epidemiological and experimental studies suggest that isoflavones may protect against breast cancer by acting as estrogen agonists or antagonists. A case-control study was conducted in southeast China in 2004-2005 to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor (ER) and progesterone receptor (PR) status. The incident cases were 756 female patients with histologically confirmed breast cancer. The 1,009 age-matched controls were healthy women randomly recruited from outpatient breast clinics. We assessed isoflavone intake by face-to-face interview using a validated and reliable food-frequency questionnaire and obtained tumor ER and PR status from pathologic reports. Compared with women in the lowest intake quartiles, those in the highest quartile of total isoflavone intake had a reduced risk of all receptor status subtypes of breast cancer with a dose-response relationship. The adjusted ORs (95% CIs) were 0.39 (0.27-0.58) for ER+, 0.32 (0.21-0.49) for ER-, 0.43 (0.29-0.64) for PR+, and 0.30 (0.19-0.45) for PR- (P for trend <0.001). These inverse associations existed in both pre- and post-menopausal women after stratification. Stronger evidence of a protective effect of high isoflavone intake was observed for breast cancer tumors with concordant rather than discordant receptor status; i.e., those with ER+/PR+ (OR 0.39, 0.26-0.59) and ER-/PR- (OR 0.28, 0.17-0.44). The finding that isoflavones protect against all tumor subtypes of breast cancer have biological plausibility, being supported by evidence from experimental studies. Future studies are required to fully understand the complex regulation of isoflavone on breast cancer by tumor hormone status. SN - 1573-7217 UR - https://www.unboundmedicine.com/medline/citation/19252980/Dietary_intake_of_isoflavones_and_breast_cancer_risk_by_estrogen_and_progesterone_receptor_status_ L2 - https://doi.org/10.1007/s10549-009-0354-9 DB - PRIME DP - Unbound Medicine ER -